Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Roy Fleischmann, Joel M. Kremer, John J. Cush et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld et al. · Arthritis & Rheumatism · 2009 · 541 citations

Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers

Attila Aranyos, David W. Old, Ayumu Kiyomori et al. · Journal of the American Chemical Society · 1999 · 528 citations

Asymmetric Catalysis, Inorganic Chemistry, Chemical Engineering +12

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 331 citations · Full text

Immunology, Janus Tyrosine Kinases, Immunotherapy +19

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

John Coombs, Bradley J. Bloom, F. C. Breedveld et al. · Annals of the Rheumatic Diseases · 2009 · 147 citations